Table 1.
Baseline characteristics
| Baseline characteristics | Total population (n = 294) | VascuQol (n = 163) | WIQ (n = 134) | Excluded patients VascuQol (n = 131) | Excluded patients WIQ (n = 160) |
|
|---|---|---|---|---|---|---|
| Age (years, SD) | 66.5 (± 10.4) (n = 271) | 66.6 (±10.3) | 65.9 (±10.1) | 66.5 (±10.6) (n = 108) | 67.1 (±10.7)(n = 137) | NS |
| Male/female gender | 163/108 (n = 271) | 95/68 | 76/58 | 68/40 (n = 108) | 87/50 (n = 137) | NS |
| Current smoker | 134 (45.9 %) (n = 292) | 72 (44.2 %) (n = 162) | 54 (40.3 %) (n = 129) | 60 (48.4 %) (n = 124) | 78 (48.8 %) (n = 152) | NS |
| History of smoking | 271 (93.1 %) (n = 291) | 141 (93.3 %) (n = 150) | 123 (91.7 %) (n = 129) | 97 (69.4 %) (n = 107) | 115 (71.8 %) (n = 128) | NS |
| Diabetes | 74 (25.2 %) (n = 284) | 43 (26.3 %) (n = 161) | 33 (24.6 %) | 31 (23.6 %) (n = 123) | 41 (25.6 %) (n = 150) | NS |
| Cardiac disease | 74 (26 %) (n = 285) | 43 (26.3 %) (n = 162) | 35 (26.1 %) | 31 (25.2 %) (n = 123) | 39 (25.8 %) (n = 151) | NS |
| Lung disease | 30 (10.2 %) (n = 84) | 17 (10.4 %) (n = 162) | 13 (9.7 %) (n = 134) | 13 (9.9 %) (n = 122) | 17 (10.6 %) (n = 150) | NS |
| eGFR | NS | |||||
| <60 | 55 (19.3 %) | 30 (18.4 %) | 25 (18.6 %) | 25 (19.1 %) | 30 (18.6 %) | |
| >60 | 162 (55.1 %) | 114 (69.9 %) | 98 (73.1 %) | 48 (36.6 %) | 64 (40 %) | |
| Unknown | 77 | 19 | 11 | 58 | 66 | |
| Previous vascular intervention | 97 (34.2 %) (n = 284) | 51 (31.3 %) (n = 160) | 40 (29.9 %) (n = 133) | 46 (35.1 %) (n = 124) | 57 (35.6 %) (n = 151) | |
| ABI at rest | P < 0.0001 | |||||
| <0.5 | 40 (13.6 %) | 30 (18.4 %) | 28 (20.9 %) | 10 (7.6 %) | 12 (7.5 %) | |
| 0.5–0.75 | 112 (38.1 %) | 83 (50.9 %) | 71 (53 %) | 29 (22.1 %) | 41 (25.6 %) | |
| 0.75–0.9 | 63 (21.4 %) | 50 (30.7 %) | 35 (26.1 %) | 13 (9.9 %) | 28 (17.5 %) | |
| 0.9–1.1 | 18 (6.1 %) | 0 | 0 | 18 (13.7 %) | 18 (11.3 %) | |
| 1.1–1.3 | 4 (1.4 %) | 0 | 0 | 4 (3.1 %) | 4 (2.5 %) | |
| unknown | 57 | 0 | 0 | 57 | 57 | |
| Affected legs | NS | |||||
| Unilateral | 125 (42.5 %) | 78 (47.9 %) | 68 (50.7 %) | 47 (35.9 %) | 57 (35.6 %) | |
| Bilateral | 130 (44.2 %) | 84 (51.5 %) | 65 (48.5 %) | 46 (35.1 %) | 65 (40.6 %) | |
| Unknown | 39 | 1 | 1 | 38 | 38 | |
| Received treatment | ||||||
| Conservative / optimal medical treatment | 113 | 47 | 40 | 66 | 73 | |
| SET | 141 | 93 | 73 | 48 | 68 | |
| Endovascular | 17 | 10 | 9 | 7 | 8 | |
| Surgical treatment | 23 | 13 | 12 | 10 | 11 | |
| Questionnaires | ||||||
| Follow-up time (days, SD) | 123 (27) | 126 (26) | ||||
| Baseline VascuQol score | 4.25 (1.2) | 4.26 (n = 119)a | NS | |||
| Baseline WIQ score | 0.39 (0.1) | 0.42 (n = 120)a | NS | |||
Data displayed as number (percentage) or mean (standard deviation)
aScore was calculated in the number of patients that did sufficiently fill in the baseline questionnaire, but were excluded for not sufficiently filling follow-up questionnaire
NS Not significant